This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Feb;133(2):231-2.

doi: 10.1001/jamaophthalmol.2014.4638.

Is combination therapy for resistant vitreous seeds really essential?

Rajesh Ramanjulu¹, Mahesh Shanmugam Palanivelu¹

Affiliations

PMID: 25393925
DOI: 10.1001/jamaophthalmol.2014.4638

Comment

Is combination therapy for resistant vitreous seeds really essential?

Rajesh Ramanjulu et al. JAMA Ophthalmol. 2015 Feb.

. 2015 Feb;133(2):231-2.

doi: 10.1001/jamaophthalmol.2014.4638.

Authors

Rajesh Ramanjulu¹, Mahesh Shanmugam Palanivelu¹

Affiliation

¹ Sankara Eye Hospital, Bangalore, India.

PMID: 25393925
DOI: 10.1001/jamaophthalmol.2014.4638

No abstract available

PubMed Disclaimer

Comment in

Is combination therapy for resistant vitreous seeds really essential? - reply.
Ghassemi F, Shields CL, Khodabande A. Ghassemi F, et al. JAMA Ophthalmol. 2015 Feb;133(2):232-3. doi: 10.1001/jamaophthalmol.2014.4657. JAMA Ophthalmol. 2015. PMID: 25394231 No abstract available.

Comment on

Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Ghassemi F, et al. JAMA Ophthalmol. 2014 Aug;132(8):936-41. doi: 10.1001/jamaophthalmol.2014.414. JAMA Ophthalmol. 2014. PMID: 24789622

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems